Search papers, labs, and topics across Lattice.
This paper introduces a hybrid quantum-classical workflow that integrates the Linear Scaling CNOT UCCSD (LCNot-UCCSD) ansatz into the Quantum Selected Configuration Interaction (QSCI) framework, significantly reducing the computational complexity of parameter initialization from $\mathcal{O}(N^6)$ to $\mathcal{O}(N^4)$. Additionally, it presents QSCI-RBM, which employs a Restricted Boltzmann Machine to enhance configuration recovery, allowing for more efficient sampling in quantum simulations. Evaluated on various molecular systems, this approach demonstrates a substantial reduction in classical resource requirements, paving the way for more accessible drug discovery simulations.
Achieving a fourfold reduction in computational complexity for quantum simulations could revolutionize drug discovery efficiency in the industry.
Calculation of binding energies for protein-ligand molecular systems requires accurate treatment of the electronic structure, a quantum chemistry problem that scales exponentially on classical hardware, while current quantum hardware remains too noisy for the required circuit depths. This report presents a hybrid quantum-classical workflow performed on the Fujitsu FX700 ideal state-vector simulator using QARP that addresses two structural inefficiencies in quantum-sampling-based diagonalization workflows. First, we integrate the Linear Scaling CNOT UCCSD (LCNot-UCCSD) ansatz into the QSCI framework, replacing the $\mathcal{O}(N^6)$ CCSD parameter initialization of the competing LUCJ ansatz approach with $\mathcal{O}(N^4)$ MP2-amplitude initialization. Second, we introduce QSCI-RBM, a variant that replaces the configuration recovery of the SQD framework with a Restricted Boltzmann Machine (RBM) acting as a compact generative subspace expansion model. Both are evaluated on eight different molecules in STO-3G across 14 controlled artificial error levels with 100 independent runs each, validated on potential energy surface scans of the N$_2$ molecule in cc-pVDZ, and embedded within DMET to treat the FDA-approved antiviral Amantadine (C$_{10}$H$_{17}$N, 11 DMET fragments) and the active region of the SARS-CoV-2 main protease complexed with its covalent inhibitor Carmofur (PDB: 7BUY, C$_{15}$H$_{28}$N$_4$O$_5$S, 10 fragments). To our knowledge, this is the first deployment of LCNot-UCCSD within QSCI on a quantum computing simulator, and the first DMET-QSCI(LCNot-UCCSD)-RBM application to an industry-relevant protein-ligand system. By utilizing a fraction of the classical computing resources required by the current state-of-the-art work by Cleveland Clinic, RIKEN, and IBM Quantum, this approach enables more efficient and economical drug discovery simulations for the industry.
